Hansoh Pharmaceutical Group Co (HKSE:03692) Interest Expense : HK$-7 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Hansoh Pharmaceutical Group Co's interest expense for the six months ended in Dec. 2024 was HK$ -2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-7 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Hansoh Pharmaceutical Group Co's Operating Income for the six months ended in Dec. 2024 was HK$ 1,446 Mil. Hansoh Pharmaceutical Group Co's Interest Expense for the six months ended in Dec. 2024 was HK$ -2 Mil. Hansoh Pharmaceutical Group Co's Interest Coverage for the quarter that ended in Dec. 2024 was 775.52. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hansoh Pharmaceutical Group Co Interest Expense Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Interest Expense Chart

Hansoh Pharmaceutical Group Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-1.95

-64.67

-64.93

-72.93

-7.14

Hansoh Pharmaceutical Group Co Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Interest Expense	Get a 7-Day Free Trial											-32.93	-33.62	-39.31	-5.32	-1.86

Hansoh Pharmaceutical Group Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-7 Mil.

Hansoh Pharmaceutical Group Co (HKSE:03692) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hansoh Pharmaceutical Group Co's Interest Expense for the six months ended in Dec. 2024 was HK$-2 Mil. Its Operating Income for the six months ended in Dec. 2024 was HK$1,446 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2024 was HK$65 Mil.

Hansoh Pharmaceutical Group Co's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2024 )	/	Interest Expense (Q: Dec. 2024 )
	=	-1	*	1445.561	/	-1.864
	=	775.52

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Hansoh Pharmaceutical Group Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Hansoh Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Interest Expense

Traded in Other Exchanges

HNSPF:USA 3KY:Germany

Address

287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210

Website

https://www.hspharm.com

Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Executives

Apex Medical Company Ltd.	2101 Beneficial owner
Cen Junda	2307 Founder of a discretionary trust who can infl
Cantrust (far East) Limited	2301 Trustee
Jqc Holding Limited	2201 Interest of corporation controlled by you
Jqc International Limited	2201 Interest of corporation controlled by you
Sun Yuan	2101 Beneficial owner
Harmonia Holding Investing (ptc) Limited	2201 Interest of corporation controlled by you
Stellar Infinity Company Ltd.	2101 Beneficial owner
Sunrise Investment Advisors Limited	2201 Interest of corporation controlled by you
Zhong Huijuan	2307 Founder of a discretionary trust who can infl

Hansoh Pharmaceutical Group Co Headlines

No Headlines